Search research articles
Contact Us
Filters
Showing results (1-10 of 60) with videos related to
Page
of 6
Sort By:
Evidence-Based Mental Health
|
July 28, 2009
No significant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms
Michela Nosè
Epidemiologia E Psichiatria Sociale
|
October 18, 2008
Tolerability of antipsychotic drugs: does patient perspective deserve consideration?
Michela Nosè
Epidemiologia E Psichiatria Sociale
|
October 18, 2008
A simple approach to manage dosages in drug-epidemiology research
Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
February 19, 2004
[Systemic review of clinical interventions for reducing treatment non-adherence in psychosis]
Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
July 1, 2008
Allocation concealment and blinding in clinical trials
Andrea Cipriani, Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
April 13, 2007
What is a risk ratio?
Andrea Cipriani, Michela Nosè, Corrado Barbui
Computer Methods and Programs in Biomedicine
|
August 9, 2006
Generating psychotropic drug exposure data from computer-based medical records
Chiara Bonetto, Michela Nosè, Corrado Barbui
Pharmacoepidemiology and Drug Safety
|
May 29, 2015
Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies
Michela Nosè, Elisabetta Recla, Gianluca Trifirò, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 10, 2005
International dosage differences in fluoxetine clinical trials
Scott Patten, Andrea Cipriani, Paolo Brambilla, et al.
International Clinical Psychopharmacology
|
October 3, 2006
Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials
Michela Nosè, Andrea Cipriani, Bruno Biancosino, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 60) with videos related to
Sort By:
Page
of 6
Evidence-Based Mental Health
|
July 28, 2009
No significant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms
Michela Nosè
Epidemiologia E Psichiatria Sociale
|
October 18, 2008
Tolerability of antipsychotic drugs: does patient perspective deserve consideration?
Michela Nosè
Epidemiologia E Psichiatria Sociale
|
October 18, 2008
A simple approach to manage dosages in drug-epidemiology research
Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
February 19, 2004
[Systemic review of clinical interventions for reducing treatment non-adherence in psychosis]
Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
July 1, 2008
Allocation concealment and blinding in clinical trials
Andrea Cipriani, Michela Nosè, Corrado Barbui
Epidemiologia E Psichiatria Sociale
|
April 13, 2007
What is a risk ratio?
Andrea Cipriani, Michela Nosè, Corrado Barbui
Computer Methods and Programs in Biomedicine
|
August 9, 2006
Generating psychotropic drug exposure data from computer-based medical records
Chiara Bonetto, Michela Nosè, Corrado Barbui
Pharmacoepidemiology and Drug Safety
|
May 29, 2015
Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies
Michela Nosè, Elisabetta Recla, Gianluca Trifirò, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|
March 10, 2005
International dosage differences in fluoxetine clinical trials
Scott Patten, Andrea Cipriani, Paolo Brambilla, et al.
International Clinical Psychopharmacology
|
October 3, 2006
Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials
Michela Nosè, Andrea Cipriani, Bruno Biancosino, et al.
Page
of 6